ArriVent Biopharma Inc (Ticker: AVBP US) is a United States-based biotechnology company specializing in the development of innovative cancer treatments. Founded in 2021, ArriVent focuses on globally developing top biopharma innovations, particularly in the field of oncology, and has a pipeline of novel candidates in-licensed from various global markets. The company's lead clinical asset, furmonertinib, exemplifies its strategy of identifying and rapidly developing first-in-class or best-in-class oncology medicines.

ArriVent Biopharma will list on NASDAQ GM on January 26, 2024. The firm is offering 9.72 million shares at a price of USD 18.00 per share. The expected market capitalization at offer is USD 550.22 million. The total offer size is USD 175.00 million. The offering is managed by Goldman Sachs (Left Lead), Citigroup Global Markets Inc, and Jefferies LLC.